Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, …, Ravaud A · 2008 · Lancet · Atlas ID MOT2008

What this study shows

Everolimus extended median progression-free survival from 1.9 to 4.0 months versus placebo in metastatic renal cell carcinoma.

Abstract

ShowHide

Everolimus (RAD001) is an orally administered inhibitor of the mammalian target of rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma. We did a phase III, randomised, double-blind, placebo-controlled trial of everolimus in patients with metastatic renal cell carcinoma whose disease had progressed on vascular endothelial growth factor-targeted therapy.

Read the full abstract on PubMed →

At a glance

Evidence type	H Human study Marked H because it is direct evidence from a human clinical trial or human cohort; the code names the kind of study, not its quality -- a small, well-run trial is still H.
Study type	2 - Human Clinical Trial
Model system	Humans, phase III RCT (RECORD-1)
Journal	Lancet
Year	2008
Peer reviewed	Yes
Record last updated	2026-10-01
Source	DOI 10.1016/S0140-6736(08)61039-9 · PMID 18653228

Extracted findings

These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.

Intervention	Everolimus (RAD001)
Target	mTORC1
Model	Human – phase III RCT (RECORD-1), metastatic renal cell carcinoma
Effect	Everolimus improved progression-free survival vs placebo after VEGF-targeted therapy failure

In the Atlas

Links in the pathway map

Supports Everolimus inhibits mTORC1
Supports Everolimus inhibits Renal cell carcinoma (RCC)
Supports mTORC1 is associated with Renal cell carcinoma (RCC)

Cite this paper

ShowHide

Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., Urbanowitz, G., Berg, W. J., Kay, A., Lebwohl, D., & Ravaud, A. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. https://doi.org/10.1016/S0140-6736(08)61039-9

@article{MOT2008,
  author       = {Motzer, R. J. and Escudier, B. and Oudard, S. and Hutson, T. E. and Porta, C. and Bracarda, S. and Grünwald, V. and Thompson, J. A. and Figlin, R. A. and Hollaender, N. and Urbanowitz, G. and Berg, W. J. and Kay, A. and Lebwohl, D. and Ravaud, A.},
  title        = {{Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial}},
  journal      = {Lancet},
  year         = {2008},
  doi          = {10.1016/S0140-6736(08)61039-9},
  note         = {PMID: 18653228},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record MOT2008) [Data set]. https://mtor-atlas.org/study/MOT2008/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_MOT2008,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record MOT2008},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/MOT2008/},
  doi          = {10.5281/zenodo.22059963}
}

Was this page useful?